HemaMax
Cancer (Oncology)
Phase 2Active
Key Facts
About Neumedicines
Neumedicines is a private, clinical-stage biotech advancing HemaMax, an immunotherapeutic designed to bridge hematopoiesis and immunity for oncology. Founded in 2004, the company is pre-revenue and targets significant unmet needs in cancer treatment by aiming to improve response rates and durability. Its strategy involves clinical development of its lead asset, supported by a team of research and medical experts and strategic collaborations. The company operates in the competitive but high-potential field of cancer immunotherapy.
View full company profileTherapeutic Areas
Other Cancer (Oncology) Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed T Cell Program | Intune | Preclinical |
| Undisclosed Cell Therapy Program | Modulus Therapeutics | Preclinical |
| In Vivo CAR-T Programs | GenVivo | Pre-clinical |